NO320773B1 - Isolert polypeptid og vektor omfattende dette, artrittogent peptid av polypeptidet og sammensetning omfattende dette for forebyggelse og behandling av reumatoid artritt. - Google Patents

Isolert polypeptid og vektor omfattende dette, artrittogent peptid av polypeptidet og sammensetning omfattende dette for forebyggelse og behandling av reumatoid artritt. Download PDF

Info

Publication number
NO320773B1
NO320773B1 NO19964910A NO964910A NO320773B1 NO 320773 B1 NO320773 B1 NO 320773B1 NO 19964910 A NO19964910 A NO 19964910A NO 964910 A NO964910 A NO 964910A NO 320773 B1 NO320773 B1 NO 320773B1
Authority
NO
Norway
Prior art keywords
peptide
arthritogenic
composition
sequence
peptides
Prior art date
Application number
NO19964910A
Other languages
English (en)
Norwegian (no)
Other versions
NO964910D0 (no
NO964910L (no
Inventor
Dennis A Carson
Albani Salvatore
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of NO964910D0 publication Critical patent/NO964910D0/no
Publication of NO964910L publication Critical patent/NO964910L/no
Publication of NO320773B1 publication Critical patent/NO320773B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO19964910A 1994-05-20 1996-11-19 Isolert polypeptid og vektor omfattende dette, artrittogent peptid av polypeptidet og sammensetning omfattende dette for forebyggelse og behandling av reumatoid artritt. NO320773B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24698894A 1994-05-20 1994-05-20
PCT/US1995/004896 WO1995031984A1 (fr) 1994-05-20 1995-04-24 Method et reactifs pour le traitement de l'arthrite rhumatoide

Publications (3)

Publication Number Publication Date
NO964910D0 NO964910D0 (no) 1996-11-19
NO964910L NO964910L (no) 1996-11-19
NO320773B1 true NO320773B1 (no) 2006-01-23

Family

ID=22933053

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19964910A NO320773B1 (no) 1994-05-20 1996-11-19 Isolert polypeptid og vektor omfattende dette, artrittogent peptid av polypeptidet og sammensetning omfattende dette for forebyggelse og behandling av reumatoid artritt.

Country Status (11)

Country Link
EP (1) EP0762881B1 (fr)
JP (1) JPH10500679A (fr)
AT (1) ATE261735T1 (fr)
AU (1) AU696646B2 (fr)
CA (1) CA2188582A1 (fr)
DE (1) DE69532714T2 (fr)
FI (1) FI964604L (fr)
HU (1) HU220101B (fr)
NO (1) NO320773B1 (fr)
NZ (1) NZ284914A (fr)
WO (1) WO1995031984A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773570A (en) * 1994-05-20 1998-06-30 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US7094597B1 (en) 1994-05-20 2006-08-22 The Regents Of The University Of California Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
US7608683B2 (en) 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US6989146B2 (en) 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
AU2002220038A1 (en) * 2000-11-01 2002-05-15 Alberto Martini Immunomodulatory peptides derived from heat shock proteins and uses thereof
DE202007003266U1 (de) 2007-03-02 2008-07-17 Bufe, Albrecht, Prof. Dr. Med. Pharmazeutische Zusammensetzung zum Schutz vor Allergien und entzündlichen Erkrankungen
EP1964570B1 (fr) 2007-03-02 2012-11-21 Protectimmun GmbH Composition pharmaceutique destinée à la protection contre les allergies et les maladies infectieuses
US20120128597A1 (en) 2008-08-16 2012-05-24 Forschungszentrum Borstel Composition for prevention and treatment of allergic and/or inflammatory diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732757A (en) * 1978-02-06 1988-03-22 Stolle Research And Development Corporation Prevention and treatment of rheumatoid arthritis
EP0474764A4 (en) * 1989-05-31 1992-11-19 Scripps Clinic And Research Foundation Method to treat rheumatoid arthritis

Also Published As

Publication number Publication date
NO964910D0 (no) 1996-11-19
FI964604A7 (fi) 1997-01-15
ATE261735T1 (de) 2004-04-15
NO964910L (no) 1996-11-19
FI964604A0 (fi) 1996-11-18
AU696646B2 (en) 1998-09-17
EP0762881A1 (fr) 1997-03-19
EP0762881A4 (fr) 1999-05-06
CA2188582A1 (fr) 1995-11-30
EP0762881B1 (fr) 2004-03-17
JPH10500679A (ja) 1998-01-20
FI964604L (fi) 1997-01-15
HU220101B (hu) 2001-10-28
MX9605692A (es) 1998-05-31
HU9603214D0 (en) 1997-01-28
DE69532714D1 (de) 2004-04-22
DE69532714T2 (de) 2005-03-10
NZ284914A (en) 2000-08-25
WO1995031984A1 (fr) 1995-11-30
HUT76359A (en) 1997-08-28
AU2360095A (en) 1995-12-18

Similar Documents

Publication Publication Date Title
JP2009278998A (ja) チロトロフィン（ｔｓｈ）受容体の抗原決定領域、その使用およびその抗体
Bockova et al. Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies
KR100328112B1 (ko) 류마토이드관절염병원관련관절염성펩티드에대항하는면역보호유도에유용한백신조성물과방법
JP3554319B2 (ja) ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物
NO320773B1 (no) Isolert polypeptid og vektor omfattende dette, artrittogent peptid av polypeptidet og sammensetning omfattende dette for forebyggelse og behandling av reumatoid artritt.
US6075119A (en) Peptides useful for reducing symptoms of toxic shock syndrome
CN101780272B (zh) 一种含有TGF β1自体疫苗制剂的应用
CN113164573B (zh) 包含修饰的MHC II类DRα1结构域的重组多肽及其应用方法
Jin et al. Long-lasting specific antibodies against P277 induced by mucosal administration of P277 repeat sequences carried by Hsp65 in the absence of adjuvants
US6946132B2 (en) Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis
JP4516914B2 (ja) Ｓｅｂ改変体およびそれを含有する免疫異常性疾患の予防・治療用剤
US20130121992A1 (en) Molecules and methods for treatment of diabetes
MXPA96005692A (es) Metodos y reactivos para el tratamiento de artritis reumatoide
Langton et al. Structural features of an antigen required for cellular interactions and for T cell activation in a MHC-restricted response.
Purdie et al. Bacterial superantigens
JP3955627B6 (ja) 糖尿病の治療のためのヒト熱ショックタンパク質６０由来の新規ペプチド、組成物、方法およびキット
JP2007119482A (ja) 糖尿病の治療のためのヒト熱ショックタンパク質６０由来の新規ペプチド、組成物、方法およびキット